Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lixte Biotechnology Holdings ( (LIXT) ) just unveiled an update.
On July 9, 2025, Lixte Biotechnology Holdings announced that the journal Nature published findings validating their clinical trials for ovarian and colorectal cancers using their compound LB100. The study, led by Dr. Amir Jazaeri, highlighted that mutations in PPP2R1A, targeted by LB100, improve survival outcomes in ovarian cancer patients. Lixte is conducting trials in collaboration with GSK and Roche to test LB100’s efficacy in combination with immunotherapies, potentially offering new treatment paradigms for cancer patients.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company is pioneering efforts in cancer biology with its lead compound, LB-100, a PP2A inhibitor, which has shown potential to enhance chemotherapies and immunotherapies.
Average Trading Volume: 2,070,583
Technical Sentiment Signal: Hold
Current Market Cap: $7.96M
Find detailed analytics on LIXT stock on TipRanks’ Stock Analysis page.